T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
2024年2月8日 - 6:05AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, announced today that it will report financial results for
the fourth quarter and full year 2023 and business updates after
market close on Thursday, February 15, 2024. Company management
will host a corresponding conference call beginning at 4:30
p.m. Eastern Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.t2biosystems.com, on the Investors page in
the Events & Presentations section. To listen to the conference
call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011
(International), passcode 106354, approximately ten to five minutes
prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistance genes, is
dedicated to improving patient care through the rapid detection of
bacterial and fungal pathogens which allow faster targeted
antimicrobial treatment. T2 Biosystems’ products are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology and include
the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel,
the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems
has an active pipeline of future products, including the U.S.
T2Resistance® Panel, expanded T2Bacteria Panel to add Acinetobacter
baumannii, the Candida auris test, and the T2Lyme™ Panel. For more
information, please visit www.t2biosystems.com.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
過去 株価チャート
から 4 2024 まで 5 2024
T2 Biosystems (NASDAQ:TTOO)
過去 株価チャート
から 5 2023 まで 5 2024